Works in Frontiers in Pharmacology, 2025


Results: 2239
    1
    2
    3
    4

    Tricin selectively combats KRAS-mutant non-small cell lung cancer by inhibiting the PDGF-BB-induced SRC/MAPK/AP-1/PD-L1 signaling pathway and potentiating the antitumor effect of an anti-PD-1 antibody.

    Published in:
    Frontiers in Pharmacology, 2025, p. 1, doi. 10.3389/fphar.2025.1594213
    By:
    • Li, Jia-Xin;
    • Tan, Shi-Yu;
    • Li, Li-Qi;
    • Zheng, Yu-Hong;
    • Zhao, Lin;
    • Zhu, Hui-Rong;
    • He, Hai-Lang;
    • Zhang, Yan-Yu;
    • Li, Run-Ze;
    • Bao, Tian-Yu;
    • Zhang, Yi-Zhong;
    • Yang, Xiao-Man;
    • Zhang, Hao;
    • Chen, Hui-Hui;
    • Wu, Bo-Wen;
    • Lin, Xin;
    • Lin, Xiao-Sheng;
    • Lin, Yin Cheng;
    • Sui, Xin-Bing;
    • Xie, Ying
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    43
    44
    45
    46
    47
    48
    49
    50